Novel lipid-regulating drugs (Q34075175)

30 July 2017

1 reference

title

Novel lipid-regulating drugs (English)

1 reference

30 July 2017

Thompson GR

1

1 reference

PubMed ID

11060824

30 July 2017

Naoumova RP

series ordinal

2

1 reference

PubMed ID

11060824

30 July 2017

language of work or name

English

0 references

publication date

1 November 2000

1 reference

Expert Opinion on Investigational Drugs

30 July 2017

1 reference

30 July 2017

9

1 reference

30 July 2017

11

1 reference

30 July 2017

2619-2628

1 reference

New prospects for lipid-lowering drugs

30 July 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.11.2619

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.11.2619

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.11.2619

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.11.2619

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.11.2619

Clinical lipidology at the end of the millennium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.11.2619

Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investiga

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.11.2619

Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.11.2619

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.11.2619

Intestinal cholesterol absorption efficiency in man is related to apoprotein E phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.11.2619

A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.11.2619

Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.11.2619

The "best" of cholesterols, the "worst" of cholesterols: a tale of two receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.11.2619

Gene transfer and hepatic overexpression of the HDL receptor SR-BI reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.11.2619

10.1517/13543784.9.11.2619

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference

PubMed ID

11060824